PDCD1 and melanoma: The results showed that SNAI2 was a powerful prognostic biomarker in urological tumors and can effectively predict the response to anti-PD-L1 immunotherapy, and consistent results were discovered in melanoma patients treated with anti-PD-1 and anti-CTLA4 therapy.